Related Experiment Video
Updated: May 8, 2026
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
Design, synthesis, and biological evaluation of novel probe-quality EGFR degraders targeting wild-type and Del19
Xiaomeng Gong1, Mingyue Zhang1, Jingli Min2
1Affiliated Yongkang First People's Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China; School of Pharmacy, Hangzhou Medical College, Hangzhou 310059, China.
Abstract:
Epidermal growth factor receptor (EGFR) serves as a key therapeutic target for solid tumors such as non-small cell lung cancer (NSCLC), where its mutations and overexpression often lead to sustained activation of oncogenic signaling pathways. This study represents a comparative analysis of multiple targeted chimeric degradation technologies targeting EGFR allosteric sites, aiming to provide clearer guidance for the future development of allosteric EGFR degraders. Results demonstrate that the VHL-based PROTAC compound III-4 exhibits optimal degradation activity against EGFRWT and EGFRDel19, degrading approximately 76% and 72% at 0.1 μM, respectively, with degradation partially dependent on the ubiquitin-proteasome pathway. For degrading the acquired resistance mutant EGFRL858R/T790M, CRBN-based PROTAC compounds II-3 and II-5 demonstrated significant efficacy (approximately 60% degradation at 0.1 μM) and effectively inhibited H1975 cell proliferation (IC50 values of 23.32 μM and 14.31 μM, respectively). In contrast, AUTAC and HyT-type compounds exhibited overall weaker degradation activity, relying on the autophagy-lysosomal pathway and proteasome pathway, respectively. Physicochemical analysis indicated that PROTAC compounds exhibited cLogP and polar surface area (PSA) values closer to the ideal range, potentially contributing to their cellular permeability and degradation activity. In summary, this study represents a deepened and extended investigation built directly on previous seminal work, aiming to provide clearer guidance for the future development of allosteric EGFR degraders.
Insights
This study compares targeted degradation technologies for epidermal growth factor receptor (EGFR) in cancer. VHL-based PROTACs effectively degrade wild-type and mutant EGFR, guiding future degrader development.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Epidermal growth factor receptor (EGFR) is a critical therapeutic target in solid tumors, including non-small cell lung cancer (NSCLC).
- Mutations and overexpression of EGFR drive oncogenic signaling, necessitating novel therapeutic strategies.
- Targeted protein degradation offers a promising approach to eliminate disease-driving proteins.
Purpose of the Study:
- To comparatively analyze various targeted chimeric degradation technologies against allosteric sites of EGFR.
- To provide guidance for the development of novel allosteric EGFR degraders.
- To evaluate the efficacy of different degradation mechanisms against wild-type and mutant EGFR forms.
Main Methods:
- Comparative analysis of VHL-based PROTACs, CRBN-based PROTACs, AUTAC, and HyT-type compounds targeting EGFR.
- Assessment of degradation activity against EGFR wild-type (EGFRWT), EGFRDel19, and EGFRL858R/T790M mutants.
- Evaluation of cell proliferation inhibition and physicochemical properties (cLogP, PSA) of tested compounds.
Main Results:
- VHL-based PROTAC compound III-4 showed optimal degradation of EGFRWT (76%) and EGFRDel19 (72%) via the ubiquitin-proteasome pathway.
- CRBN-based PROTACs II-3 and II-5 effectively degraded EGFRL858R/T790M (approx. 60%) and inhibited H1975 cell proliferation.
- PROTAC compounds exhibited favorable physicochemical properties (cLogP, PSA) compared to other technologies.
Conclusions:
- VHL-based PROTACs are highly effective for wild-type and common EGFR mutants.
- CRBN-based PROTACs demonstrate potential for targeting acquired resistance mutations like EGFRL858R/T790M.
- This study provides valuable insights for designing next-generation allosteric EGFR degraders.
